Investors
News
Subscribe
Hit enter to search or ESC to close
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Cardiovascular Disease
Metabolic Disease
Liver Disease
Arthritis
Aging
Coronavirus Disease 2019 (COVID-19)
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
Press Releases
Investor Relations
Investors
Overview
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
Company Info
Profile
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All News
2023
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2007
2006
Cardax Promotes David M. Watumull to COO; Partially Restores Compensation Company-Wide
Sep 7, 2017
Cardax Attracts $2.75M in Investment
Aug 28, 2017
Cardax Reports Q2 2017 Results
Aug 11, 2017
ZanthoSyn Going National with GNC
Aug 10, 2017
ZanthoSyn Now Available on GNC.com
Jun 27, 2017
Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program
Jun 18, 2017
Cardax Q1 2017 Revenues Triple vs. Prior Two Quarters Combined
May 15, 2017
Cardax Astaxanthin Compound CDX-085 Stimulates Anti-Aging Gene in Mice
Mar 28, 2017
Cardax Secures Access to Funds Under Equity Purchase Agreement
Feb 9, 2017
Cardax Takes Important Step to Access Funds Under Equity Purchase Agreement
Feb 8, 2017
1
2
3
4
5
6
7
8
9
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Investor Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Contact Us
Investors
News
Subscribe
